Navigation Links
Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
Date:1/15/2009

ults of this pilot study, we anticipate that hGH-CTP could potentially achieve weekly or bi-monthly dosing frequency in humans."

Dr. Havron added, "We look forward to completing these toxicology studies and finalizing the IND for hGH-CTP in the coming months. We are pleased too that our current cash resources should enable us to complete the hGH-CTP Phase I clinical program and continue into Phase II trials over the next 24 months."

ABOUT hGH-CTP (MOD-4023)

hGH-CTP, also known as MOD-4023, is Modigene's proprietary long-acting version of human growth hormone. hGH is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone. Patients using hGH must currently inject the drug between two and seven times each week, a frequency that can be particularly burdensome for pediatric patients. In contrast, hGH-CTP is expected to require only weekly or bi-monthly injections. The primary indications for hGH in children are growth hormone deficiency, kidney disease, Prader-Willi Syndrome and Turner Syndrome. In adults, the primary indications are replacement of endogenous growth hormone and the treatment of AIDS-induced weight loss. In 2007 the annual market for hGH was estimated at $2.5 billion. In addition to its use for medical indications, hGH has been shown to promote a number of "lifestyle" benefits including reversal of non-voluntary weight loss, increased energy levels, enhanced sexual performance, lower cholesterol and improved appearance of the skin.

ABOUT CTP

Modigene's CTP technology was discovered by researchers at Washington University in St. Louis and is based on a short amino acid sequence that occurs naturally in humans, the carboxyl terminal peptide (CTP). When attached to a therapeutic protein, CTP extends the time that the protein is active in the body. The potential utility of the tec
'/>"/>

SOURCE Modigene Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
2. Modigene Platform Validated in Independent Phase III Trial of CTP Technology
3. Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Amgen (NASDAQ: AMGN ... partner and managing director of Warburg Pincus LLC, to the ... to welcome Fred Hassan and the deep, global ... Board," said Robert A. Bradway , chairman and chief ... to innovation will serve Amgen well." Mr. Hassan ...
(Date:7/30/2015)...  Cleveland Clinic President Wael Barsoum , M.D. ... that industry is compelled to adopt declining reimbursements throughout ... develop the transformational innovations -- required to thrive in ... by Doug Kohrs , past President and CEO ... that industry must add "episode of care," also known ...
(Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Aug. 4 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... submitted to the FDA a pre-IDE (Investigational Device,Exemption) ... assay,for detection of early lung cancer in veterans. ... million over two years towards the,study that will ...
... Rx, a specialty,pharmaceutical company leveraging its proprietary ... products, today announced the,completion of pilot product ... oxalate, a selective serotonin reuptake inhibitor.,Escitalopram oxalate ... and is marketed under the brand name ...
Cached Medicine Technology:FDA Reviewing Biomoda Submission for Cancer Screening Study 2MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development 2MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development 3
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, ... on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. ... this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... players to know in predictive health analytics , Jvion continues to disrupt ... firm creates predictive software that targets patient and population level illness to drive ...
(Date:7/31/2015)... Memphis, Tenn. (PRWEB) , ... July 31, 2015 , ... ... at Robert Church Park in Downtown Memphis on October 3, 2015. The Ride to ... partnership focused on cancer research between Methodist Healthcare, The West Clinic and The University ...
(Date:7/31/2015)... , ... July 31, 2015 , ... There’s no better ... even when it comes time to cook the next meal, making July the most ... by practicing best grilling tips and recipes. , Make the next cookout different than ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... Oct. 17 40|86 Strategic Income,Fund (NYSE: CFD ... 9, 2007 to holders of record at the close ... Fund is a closed-end investment management,company. The Fund,s primary ... in the Fund,s prospectus, the Fund intends to,distribute substantially ...
... Symmetry Medical Inc.,(NYSE: SMA ), an independent ... and other medical markets, announced today the appointment,of ... November 1,2007. Mr. Hynes will assume responsibility ... Europe including the UK, Ireland,France and Switzerland. He ...
... (Oct. 17, 2007) -- Two reports from physician-scientists at ... male infertility. A first report shows that a common ... in the scrotum -- also results in a depletion ... that once a common, simple surgery is used to ...
... cancer screening practices, , , WEDNESDAY, Oct. 17 (HealthDay News) -- ... most cervical cancers -- was far better than the standard ... What,s unclear, however, is whether or not the HPV test ... have a slightly higher false positive rate, and it,s not ...
... in men, it could lead to new treatments, study says, ... a gene that,s essential for the formation of functioning sperm ... from being able to penetrate an egg. , The finding, ... Hill, was based on research with mice. But it might ...
... Oct. 17 Good oral health and good ... 15-19) is a great,opportunity to ensure that children ... the nation,s premier, independent oral health advocacy,organization is ... to promote healthy school lunches. Children who learn,good ...
Cached Medicine News:Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 2Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 3Health News:The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell 2Health News:HPV Test Bests Pap Smear in Studies 2Health News:HPV Test Bests Pap Smear in Studies 3Health News:Gene Mutation Key to Infertility in Male Mice 2Health News:Oral Health America Celebrates National School Lunch Week 2
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
BD Visitec IOL Manipulator, blunt tip, formed 10.0mm from end. Fits 0.20mm diameter holes & larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge indicating positio...
BD Visitec IOL Manipulator (Lester), 0.25 mm diameter tip angled 45 in, 10 mm from end (3/bx, 1 bx/ca), sterile. For positioning intraocular lenses. Sure grip handles hand ridge indicating position o...
Lewicky lens manipulator. Also available in titanium....
Medicine Products: